Kidney Disease Following Hematopoietic Stem Cell Transplantation

Ala Abudayyeh; Rimda Wanchoo

doi:10.1053/j.ackd.2021.11.003

Kidney Disease Following Hematopoietic Stem Cell Transplantation

Adv Chronic Kidney Dis. 2022 Mar;29(2):103-115.e1. doi: 10.1053/j.ackd.2021.11.003.

Authors

Ala Abudayyeh¹, Rimda Wanchoo²

Affiliations

¹ Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY. Electronic address: rwanchoo1@northwell.edu.

PMID: 35817518
DOI: 10.1053/j.ackd.2021.11.003

Abstract

Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.

Keywords: Acute kidney injury; Allogeneic stem cell transplant; Chronic kidney disease; Hepatic sinusoidal obstruction; Thrombotic microangiopathy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Graft vs Host Disease* / complications
Graft vs Host Disease* / therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Renal Insufficiency, Chronic* / complications
Thrombotic Microangiopathies* / etiology
Thrombotic Microangiopathies* / therapy
Transplantation Conditioning / adverse effects